ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

Farudodstat

Target: DHODH

ASLAN003 is an oral inhibitor of dihydroorotate dehydrogenase (DHODH) and is currently in development for autoimmune disease. ASLAN003 is a highly selective and potent inhibitor of DHODH (IC50 = 35nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in assays than the first-generation inhibitor teriflunomide. Existing DHODH inhibitors have associated toxicities requiring safety monitoring that make them less suited as long term treatment options. New data from a study conducted by the University of Liverpool, UK, published in the Toxicology in Vitro Journal in 2021, demonstrated that, out of a panel of six DHODH inhibitors tested, ASLAN003 has the lowest potential for hepatotoxicity despite being one of the most potent inhibitors of DHODH.

Phase

Phase 1

ASLAN003 has been shown to be well tolerated at doses up to 400mg/day in 119 subjects across Phase 1 and Phase 2 clinical studies and is suitable for once-daily oral dosing. We are currently finalising a clinical development plan for ASLAN003 in autoimmune disease.

Based on the specificity, potency and favourable safety profile identified in earlier clinical studies, we believe ASLAN003 may offer best-in-class potential as a treatment for autoimmune conditions, where a pressing need for differentiated and convenient treatment options exists.